It’s a bad time for Big Pharma in India. First the Intellectual Property Appellate Board upheld the first ever compulsory licence handed out to NATCO to sell Bayer’s blockbuster cancer drug Nexavar, then another company …
That the compulsory licence verdict in favour of NATCO Pharma would change the landscape of the pharma industries the world over was never in doubt. The verdict was hailed as ‘revolutionary’, ‘path-breaking’ and hailed as …
India is a ‘hip and happening country’ when it comes to litigations in the pharmaceutical and biotechnology sectors, said a leading patent attorney said on Thursday. ‘I can definitely say that India is a happening country …
In what has been billed as landmark ruling the Intellectual Property Appellate Board upheld the country’s first compulsory licence to NATCO Pharma for Bayer’s cancer drug Nexavar recently. In layman language, NATCO, an Indian …
Compulsory licences are here to stay. The Intellectual Property Appellate Board (IPAB) on Monday upheld the country’s first compulsory licence to the Hyderabad based NATCO Pharma for Bayer’s cancer drug Nexavar setting a …
On Wednesday, India told the US that the compulsory licence given to replicate Bayer’s patented anti-cancer drug Nexavar didn’t violate any multilateral trade agreement. It also said that such a move shouldn’t be seen as …
India has always been a major thorn for Big Pharma and reiterated its stand by revoking a patent granted six years ago to Roche’s Hepatitis C drug Pegasys. The Intellectual Property Appellate Board (IPAB) deemed that there was …
In a path-breaking move that will help bring HIV medicine to the masses, drug giant Gilead Sciences signed deals with three Indian firms, including Ranbaxy Laboratories to collaborate on providing low-cost generic versions of its …
Even as President Barack Obama is plugging his signature law to lower health care costs at home, his administration is pressurising India and other countries to impose higher prices even for lifesaver cancer drugs. Obama …
